Novel psoriasis therapies and patient outcomes, part 1: Topical medications

Meghan A. Feely, Barry L. Smith, Jeffrey M. Weinberg

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


In recent years, advances in our understanding of inflammatory mediators and the underlying pathogenesis of psoriasis and psoriatic arthritis have shed light on potential therapeutic targets, which has led to the development of several new promising treatments. In this article, key clinical trials, mechanisms of action, patient outcomes, and relevant safety information for these novel topical medications will be evaluated. This article is the first in a 3-part series on treatments presently in the pipeline for the management of psoriasis and psoriatic arthritis including topical agents, biologic treatments, and systemic therapies in phase 2 and phase 3 clinical trials. With novel approaches to the disease process, these therapies may afford more targeted individualized treatment regimens and offer hope to patients with psoriasis and psoriatic arthritis who have reported a suboptimal therapeutic response to conventional therapies.

Original languageEnglish
Pages (from-to)164-168 and 170
Issue number3
StatePublished - 2015


Dive into the research topics of 'Novel psoriasis therapies and patient outcomes, part 1: Topical medications'. Together they form a unique fingerprint.

Cite this